Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1219 of 5804
-
AI could uncover silent heart failure in diabetes patients
Knowledge-focused Recruiting nowA pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Stroke recovery gets a boost: modified cardiac rehab targets body and mind
Symptom relief Recruiting nowCardiac rehabilitation is the standard-of-care treatment option for patients with cardiovascular disease and has been shown to improve many aspects critical to patient recovery. Investigators believe that individuals who have had a stroke need to be treated similarly. Investigato…
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
5-Day brain zaps aim to ease postpartum depression
Symptom relief Recruiting nowWe are studying a treatment for depression called accelerated Transcranial Magnetic Stimulation (TMS) among pregnant and postpartum individuals. TMS is a focal, non-invasive form of brain stimulation that is cleared by the Food and Drug Administration for depression. Typically, t…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 26, 2026 14:35 UTC
-
New ALS drug injected into spine begins human testing
Disease control Recruiting nowThe purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to chec…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy aims to tame kidney disease
Disease control Recruiting nowThe primary objectives of this clinical trial is to evaluate the safety and tolerability of HLX79 in combination with HLX01 versus placebo in combination with HLX01 in the treatment of glomerulonephritis. The secondary objective are to evaluate the pharmacokinetics (PK), pharmac…
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
RSV booster shot shows promise for seniors
Disease control CompletedThe purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a simple heparin shot save stroke Patients' arteries?
Disease control CompletedCerebral angiography is a critical diagnostic tool in neurology, serving as the "gold standard" for evaluating cerebrovascular stenosis, hemodynamics, aneurysms, and arteriovenous malformations. Compared to the traditional transfemoral approach, transradial cerebral angiography (…
Phase: PHASE3 • Sponsor: Xiang Luo • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New biologic FB102 takes on celiac disease in Mid-Stage trial
Disease control Recruiting nowThis study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.
Phase: PHASE2 • Sponsor: Forte Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug YL202 targets tough cancers in latest trial
Disease control Recruiting nowThis study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
Phase: PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a single IV dose rewire PTSD memories? new trial investigates.
Symptom relief Recruiting nowPurpose: About 6.4% of the U.S. population suffers from posttraumatic stress disorder (PTSD). Trauma-focused psychotherapies are generally effective in PTSD, but responses vary greatly across individuals and PTSD subpopulations. Neurobiological factors impacted by life experience…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
New CT technique could spot stomach cancer spread without surgery
Diagnosis OngoingThis study prospectively collected spectral CT imaging data and clinical information related to gastric cancer, evaluated the diagnostic efficacy of its image quality for regional lymph nodes in gastric cancer, and explored its application value in the N staging of gastric cancer…
Phase: NA • Sponsor: Yunnan Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
New proton beam machine tested for tumor control
Disease control OngoingThis trial will enroll 47 subjects who will be be treated with the IBA PROTEUS® PLUS Proton Beam radiation Therapy (PBT) medical device. The trial aims to assess the safety and efficacy of PROTEUS® PLUS for radiation therapy to oncology patients, and to provide a clinical basis …
Phase: NA • Sponsor: Ion Beam Applications • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could a diabetes drug fix period problems in teens with type 1?
Disease control ENROLLING_BY_INVITATIONThe aim of this study is to measure the frequency of menstrual irregularities among adolescent females with Type 1 diabetes mellitus and to assess the therapeutic effect of glucagon-like peptide-1 receptor agonist on menstrual irregularities in adolescent females with Type 1 diab…
Phase: PHASE1, PHASE2 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for advanced cancer: OBI-902 trial launches
Disease control Recruiting nowThis is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further cha…
Phase: PHASE1, PHASE2 • Sponsor: OBI Pharma, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Zapping the brain to beat Post-Stroke fatigue and boost speech
Symptom relief Recruiting nowThe goal of this clinical trial is to determine if electrical brain stimulation applied to the front parts of the brain can help people who have had a stroke improve their fatigue, language, and attention. The main question it aims to answer is: * Does transcranial direct curren…
Phase: NA • Sponsor: Syracuse University • Aim: Symptom relief
Last updated Jun 26, 2026 12:40 UTC
-
Radioactive beads aim to shrink inoperable liver tumors
Disease control Recruiting nowThe main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma. Other purposes of this study include assessment of the effect of treatment on overall survival, th…
Phase: PHASE1 • Sponsor: Suzhou Mednovo Yi Medical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New schizophrenia drug emraclidine enters Mid-Stage trial
Disease control Recruiting nowSchizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy aims to heal wounds in rare skin disease
Disease control Recruiting nowThe study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, an…
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Heart artery procedure plus drugs may boost heart function in ischemic cardiomyopathy
Disease control Recruiting nowTo compare the effects of physiology- and imaging-guided PCI combined with optimal medical therapy (OMT) versus OMT alone on the recovery of left ventricular systolic function in patients with ischemic cardiomyopathy and multivessel coronary artery disease.
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
No breathing tube needed: new lung transplant approach tested
Disease control CompletedThis prospective, single-center, single-arm study evaluates the feasibility, safety, and rapid recovery outcomes of a tubeless strategy in lung transplantation. Consecutive eligible adult lung transplant recipients undergo lung transplantation without standard endotracheal intuba…
Phase: NA • Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC